Prenetics Global Ltd. (NASDAQ:PRE) has reported financial results for the fourth quarter and full year 2025, delivering revenue that significantly exceeded analyst expectations and a narrower-than-anticipated loss. The market reaction in after-hours and pre-market trading appears cautiously positive, reflecting investor approval of the company's accelerating growth and strategic transformation.
Earnings and Revenue Versus Estimates
The company's flagship consumer health brand, IM8, was the primary driver behind a substantial top-line beat. For the fourth quarter, Prenetics reported revenue of $36.6 million, marking a staggering 457% increase year-over-year. This result comfortably surpassed the analyst consensus estimate of $33.8 million.
On the bottom line, the company reported a non-GAAP loss per share of $0.27. This figure represents a meaningful improvement compared to the analyst estimate for a loss of $0.35 per share. The outperformance on both key metrics underscores the rapid scaling and improving operational efficiency of the IM8 business.
-
Q4 2025 Reported Revenue: $36.6 million
-
Q4 2025 Analyst Revenue Estimate: $33.8 million
-
Result: Beat by approximately $2.8 million
-
Q4 2025 Reported Non-GAAP EPS: -$0.27
-
Q4 2025 Analyst EPS Estimate: -$0.35
-
Result: Beat by $0.08 per share
Market Reaction and Price Action
The stock's performance following the earnings release suggests a favorable reception from investors. In the immediate aftermath and during subsequent trading sessions, shares of Prenetics have shown notable strength. Over the past month, the stock has advanced approximately 38%, with a significant portion of that gain likely attributable to growing optimism ahead of the earnings report and the subsequent confirmation of strong growth.
This positive price action indicates that the market is rewarding the company for its execution, particularly the explosive growth of IM8 and the successful streamlining of its operations. The beat on both revenue and earnings estimates, coupled with a robust outlook, has provided validation for the company's strategic pivot.
Strategic Transformation and IM8 Breakout
The earnings report detailed a year of profound strategic change for Prenetics, which has successfully transformed itself into a focused, IM8-centric platform. Key highlights from the announcement include:
- Record Growth: Full-year 2025 revenue surged 480% year-over-year to $92.4 million, driven by IM8, which contributed $60.1 million in its first full fiscal year.
- IM8 Milestone: The brand achieved approximately $120 million in annualized recurring revenue (ARR) by December 2025, just 12 months after launch, reaching $10 million in monthly revenue.
- Portfolio Simplification: The company completed the divestiture of several non-core assets, including the sale of its stake in Insighta to Tencent for $70 million. These moves have bolstered the balance sheet, with the company reporting approximately $171 million in total adjusted liquidity and zero debt as of mid-February 2026.
- Improved Unit Economics: IM8 demonstrated strong capital efficiency, with a payback period of 3.5 months and a high customer subscription rate of approximately 80%. A strategic shift toward quarterly subscriptions has recently driven the blended average order value to approximately $233.
Forward Outlook and Analyst Comparisons
Looking ahead, management provided explicit guidance for its core IM8 business in 2026, which can be compared to broader analyst estimates for the entire company.
Prenetics reaffirmed its IM8 revenue guidance of $180 million to $200 million for the full year 2026. This implies a near-tripling of the brand's revenue compared to 2025. Meanwhile, the current consensus analyst estimate for Prenetics' total sales in 2026 stands at approximately $219.4 million. The company's IM8-specific guidance, which does not include other smaller segments like CircleDNA, appears to be in the ballpark of overall market expectations, suggesting analysts are modeling for similar aggressive growth.
For the first quarter of 2026, analysts are estimating total company revenue of approximately $46.4 million. Prenetics did not provide specific Q1 guidance, but the sequential momentum from Q4's $36.6 million result will be closely watched.
The company expects its adjusted EBITDA loss for 2026 to be in the range of $16 million to $20 million, similar to the past two years, while targeting a path to adjusted EBITDA profitability by the fourth quarter of 2027.
Conclusion
Prenetics' fourth-quarter earnings report paints a picture of a company in the midst of a successful reinvention. By decisively beating revenue and earnings estimates, showcasing the meteoric rise of its IM8 brand, and fortifying its balance sheet through strategic divestitures, the company has given investors clear reasons for optimism. The positive market reaction reflects approval of this execution. The primary challenge ahead will be to maintain IM8's exceptional growth trajectory and demonstrate the operating leverage needed to achieve profitability as outlined.
For a detailed breakdown of historical earnings and future analyst estimates, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.